News

Ongoing stage 2a clinical trials for Pfizer‘s Oxbryta (voxelotor) continue to show successful results in pediatric patients. Approved for treating SCD, the oral medication prevents red blood cells from sickle-shaping …

A Phase 2/3 multicenter study of Osivelotor has been approved to proceed by India’s Central Drugs Standard Control Organisation (CDSCO). Aimed at treating Sickle Cell Disease, the drug (GBT021601) has …

A clinical trial led by Dr. Ali Taher at the American University of Beirut Medical Center, shows that Mitapivat has potential benefits for non-transfusion dependent thalassemia patients. Developed by Agios …

Tim Randolph has been recognized by the National Academy of Inventors for his innovative work in developing more accessible diagnostics for sickle cell disease. The research has led to the …

We are happy to see Functional Fluidics expanding to Africa and setting up a new research clinic and laboratory in Nigeria. And we are truly grateful for the significant contributions …

The Department of Health of Puerto Rico has granted authorization to market Endari, an oral powder treatment for sickle cell disease (SCD). The first FDA-backed oral glutamine, Endari has been …

Sickle cell disease affects a significant number of individuals in North Carolina, particularly within the Black community, where about 95 percent of cases are found. This genetic blood disorder not …

A recent study conducted in Uganda revealed that treatment with hydroxyurea significantly reduced the incidence of severe or invasive infections among children with sickle cell anemia by 60%. Sickle cell …

The first patient has been administered with BEAM-101 in the BEACON trial, a Phase 1/2 clinical study conducted by Beam Therapeutics for sickle cell disease (SCD). Following the transplantation, stem …